Specifically, they performed CD19 CAR transduction in induced pluripotent stem cell-derived NK (iNK) cells, and they observed that the treatment of GBM-blood vessel assembloid (GBVA) xenografts with CD19 CAR-iNK cells exhibits greater antitumor efficacy (Kong et al., 2024). This evidence concerns the gene CD19 and glioblastoma.